fexofenadine

出典: meddic

フェキソフェナジン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/07/15 19:22:46」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spot.
  • Bosilkovska M1, Samer CF2, Déglon J3, Rebsamen M4, Staub C3, Dayer P2, Walder B5, Desmeules JA2, Daali Y2.Author information 1Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.21] Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland [2] Swiss Center for Applied Human Toxicology, Geneva, Switzerland.3Unit of Toxicology, University Center of Legal Medicine, Geneva, Switzerland.4Department of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.5Division of Anesthesiology, Geneva University Hospitals, Geneva, Switzerland.AbstractThe capillary dried blood spot (DBS) sampling method suitability was assessed for simultaneous cytochromes P450 (CYP) and P-glycoprotein (P-gp) phenotyping using a cocktail approach.Ten volunteers received an oral cocktail capsule containing low dose probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A) and fexofenadine (P-gp) with coffee/Coke (CYP1A2) on four occasions. They received the cocktail alone (session 1), with CYP inhibitors fluvoxamine and voriconazole (session 2) and quinidine (session 3). In session 4, subjects received the cocktail after a 7-day pre-treatment with inducer rifampicin. Probes/metabolites concentrations were determined in DBS and plasma using a single LC-MS/MS method.The drugs pharmacokinetic profiles were comparable in DBS and plasma. Important modulation of CYP and P-gp activities was observed in presence of inhibitors and inducer. Minimally invasive 1-point and 3-point (at 2, 3 and 6h) DBS sampling methods were found to reliably reflect CYPs and P-gp activities at each session.Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 10 April 2014 doi:10.1038/clpt.2014.83.
  • Clinical pharmacology and therapeutics.Clin Pharmacol Ther.2014 Apr 10. doi: 10.1038/clpt.2014.83. [Epub ahead of print]
  • The capillary dried blood spot (DBS) sampling method suitability was assessed for simultaneous cytochromes P450 (CYP) and P-glycoprotein (P-gp) phenotyping using a cocktail approach.Ten volunteers received an oral cocktail capsule containing low dose probes bupropion (CYP2B6), flurbiprofen (CYP2C9),
  • PMID 24722393
  • Hypoxia/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood-brain barrier: relevance to CNS drug delivery.
  • Thompson BJ1, Sanchez-Covarrubias L2, Slosky LM2, Zhang Y2, Laracuente ML2, Ronaldson PT3.Author information 1Department of Physiology, University of Arizona College of Medicine, Tucson, Arizona, USA.2Department of Pharmacology, University of Arizona College of Medicine, Tucson, Arizona, USA.31] Department of Physiology, University of Arizona College of Medicine, Tucson, Arizona, USA [2] Department of Pharmacology, University of Arizona College of Medicine, Tucson, Arizona, USA.AbstractCerebral hypoxia and subsequent reoxygenation stress (H/R) is a component of several diseases. One approach that may enable neural tissue rescue after H/R is central nervous system (CNS) delivery of drugs with brain protective effects such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (i.e., statins). Our present in vivo data show that atorvastatin, a commonly prescribed statin, attenuates poly (ADP-ribose) polymerase (PARP) cleavage in the brain after H/R, suggesting neuroprotective efficacy. However, atorvastatin use as a CNS therapeutic is limited by poor blood-brain barrier (BBB) penetration. Therefore, we examined regulation and functional expression of the known statin transporter organic anion transporting polypeptide 1a4 (Oatp1a4) at the BBB under H/R conditions. In rat brain microvessels, H/R (6% O2, 60 minutes followed by 21% O2, 10 minutes) increased Oatp1a4 expression. Brain uptake of taurocholate (i.e., Oap1a4 probe substrate) and atorvastatin were reduced by Oatp inhibitors (i.e., estrone-3-sulfate and fexofenadine), suggesting involvement of Oatp1a4 in brain drug delivery. Pharmacological inhibition of transforming growth factor-β (TGF-β)/activin receptor-like kinase 5 (ALK5) signaling with the selective inhibitor SB431542 increased Oatp1a4 functional expression, suggesting a role for TGF-β/ALK5 signaling in Oatp1a4 regulation. Taken together, our novel data show that targeting an endogenous BBB drug uptake transporter (i.e., Oatp1a4) may be a viable approach for optimizing CNS drug delivery for treatment of diseases with an H/R component.
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.J Cereb Blood Flow Metab.2014 Apr;34(4):699-707. doi: 10.1038/jcbfm.2014.4. Epub 2014 Jan 29.
  • Cerebral hypoxia and subsequent reoxygenation stress (H/R) is a component of several diseases. One approach that may enable neural tissue rescue after H/R is central nervous system (CNS) delivery of drugs with brain protective effects such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor
  • PMID 24473481
  • Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.
  • Martinez JM1, Khier S, Morita S, Rauch C, Fabre D.Author information 1Disposition, Safety and Animal Research, Drug Disposition, Modeling and Simulations Entity, Sanofi-aventis Recherche & Développement, 371, rue du Professeur Joseph Blayac, 34184, Montpellier Cedex 04, France, jean-marie.martinez@sanofi.com.AbstractA population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-time points. The analysis was performed with NONMEM using the SAEM method. Several structural models and residual error models were evaluated. The relationship between the individual estimates and the potential covariates was then investigated: demographic and pathophysiologic characteristics were tested as potential model covariates (forward selection method). The qualification of the model was performed using visual predictive check and bootstrap. A two-compartment disposition model with first-order absorption best fitted the data. The inter-individual variability was modeled through an exponential error model for all parameters (except for ka for which no inter-individual term could be estimated), while a proportional error model was used to model the residual variability. The final model included two covariates on elimination clearance and one on the intercompartmental clearance. CL/F was related to BSA and patient's age (expressed in months) Q/F was also related to BSA. Once the model was correctly qualified, exposure parameters such as Cmax and AUCτ were computed and compared between each age sub-group and between Japanese and Caucasians patients. These comparisons did not reveal any major difference (less than 50 %) between subgroups.
  • Journal of pharmacokinetics and pharmacodynamics.J Pharmacokinet Pharmacodyn.2014 Apr;41(2):187-95. doi: 10.1007/s10928-014-9356-2. Epub 2014 Mar 16.
  • A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of
  • PMID 24633780

和文文献

  • 季節性アレルギー性鼻炎に対するフェキソフェナジン塩酸塩と塩酸プソイドエフェドリン配合剤の有効性及び安全性の検討 : 第?/?相,ランダム化,二重盲検,並行群間比較試験
  • 大久保 公裕
  • アレルギー・免疫 19(11), 1770-1782, 2012-11
  • NAID 40019464573
  • 治療 蕁麻疹・湿疹皮膚炎群(湿疹・皮膚炎・皮膚痒症・アトピー性皮膚炎)に伴う痒患者における塩酸フェキソフェナジンの効果と安全性(眠気)についての検討
  • 伊藤 宏太郎,今福 信一,山口 和記 [他]
  • 西日本皮膚科 = The Nishinihon journal of dermatology : 日本皮膚科学会西部支部機関誌 74(5), 548-552, 2012-10
  • NAID 40019476261

関連リンク

Fexofenadineとは?goo Wikipedia (ウィキペディア) 。出典:Wikipedia(ウィキペディア)フリー百科事典。 Fexofenadineとは - goo Wikipedia (ウィキペディア) gooトップ サイトマップ スタートページに設定 RSS ヘルプ メニューへスキップ ...
Fexofenadine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: headache dizziness diarrhea vomiting pain in the arms, legs, or back pain pain during menstrual period cough ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元フェキソフェナジン」「Allegra
拡張検索fexofenadine hydrochloride

フェキソフェナジン」

  [★]

fexofenadine
塩酸フェキソフェナジン fexofenadine hydrochloride
アレグラ
テルフェナジン
  • 第二世代ヒスタミン薬
  • ピペリジン系



Allegra」

  [★]

アレグラ

fexofenadinefexofenadine hydrochloride

fexofenadine hydrochloride」

  [★]



★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡